Researchers continue to excited about the medication , a novel dual agonist showing remarkable results in clinical trials for weight management. It functions by targeting two pathways : GLP-1 and GIP, https://nanadmbt622324.mpeblog.com/73504801/the-new-possibility-for-body-loss